LivaNova PLC
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LIVN research report →
Companywww.livanova.com
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
- CEO
- Vladimir A. Makatsaria
- IPO
- 2015
- Employees
- 2,900
- HQ
- London, GB
Price Chart
Valuation
- Market Cap
- $4.05B
- P/E
- 37.63
- P/S
- 2.82
- P/B
- 3.33
- EV/EBITDA
- 16.50
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 67.57%
- Op Margin
- 14.16%
- Net Margin
- 7.47%
- ROE
- 9.13%
- ROIC
- 10.19%
Growth & Income
- Revenue
- $1.39B · 10.74%
- Net Income
- $-242,500,000 · -483.50%
- EPS
- $-4.45 · -480.34%
- Op Income
- $199.40M
- FCF YoY
- 27.42%
Performance & Tape
- 52W High
- $74.32
- 52W Low
- $41.02
- 50D MA
- $64.46
- 200D MA
- $60.14
- Beta
- 0.82
- Avg Volume
- 889.47K
Get TickerSpark's AI analysis on LIVN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 30, 26 | Tezel Ahmet | other | 13,873 |
| Mar 30, 26 | Tezel Ahmet | other | 3,408 |
| Mar 30, 26 | Tezel Ahmet | other | 3,408 |
| Mar 30, 26 | Tezel Ahmet | other | 4,624 |
| Mar 30, 26 | Tezel Ahmet | other | 1,186 |
| Mar 30, 26 | Poletti Franco | other | 3,184 |
| Mar 30, 26 | Poletti Franco | other | 1,370 |
| Mar 30, 26 | Poletti Franco | other | 2,130 |
| Mar 30, 26 | Poletti Franco | other | 558 |
| Mar 30, 26 | Poletti Franco | other | 325 |
Our LIVN Coverage
We haven't published any research on LIVN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LIVN Report →